Skip to main content

Table 3 Adjunct antithrombotic therapy

From: Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients

Site

Emergency unit

Catheter lab

Coronary unit and/or ward

Home use duration

Drug

    

Aspirin

300 mg orally

No

100 mg per day orally

100 mg per day orally, indefinitely

Clopidogrel

600 mg orally

No

75 mg per day orally

75 mg per day orally, 12 months

Prasugrel

60 mg orally

No

10 mg per day orally

10 mg per day orally, 12 months

Ticagrelor

180 mg orally

No

90 mg twice daily orally

90 mg twice daily orally, 12 months

Enoxaparin

1 mg per kg SC

0.3 mg per kg IV if the last dose is 8 to 12 hours 0.5 to 0.75 mg per kg IV if the last dose is >12 hours

1 mg per kg SC twice daily

No

Fondaparinux

2.5 mg SC

85 UI per kg IV UFH or 60 UI per kg IV UFH if GPI is scheduled

2.5 mg/SC/day

No

Abciximab

No

Intravenous loading dose of 0.25 mg per kg

0.125 mcg per kg per min for 12 hours, IV, without using HNF

No

Tirofiban

No

Intravenous loading dose of 25 mcg per kg

0.15 mcg per kg per min for 12 to 18 hours, IV, without using HNF

No

  1. GPI, IIb-IIIa glycoprotein receptor inhibitor; UFH; unfractionated heparin, IV, intravenous; SC subcutaneous.